Fibrin Sealant Patch (TachoSil) vs Oxidized Regenerated Cellulose Patch (Surgicel Original) for the Secondary Treatment of Local Bleeding in Patients Undergoing Hepatic Resection: A Randomized Controlled Trial - 03/03/16
, Tomoaki Kato, MD, FACS b, James J. Pomposelli, MD, FACS c, J Kelly Wright, MD, FACS d, Linda S. Sher, MD, FACS a, Vilhelm Tetens, PhD e, William C. Chapman, MD, FACS fAbstract |
Background |
Local hemostatic agents are important for the control of bleeding during liver resection when standard surgical techniques are insufficient.
Study Design |
This was a multicenter, randomized, open-label study to compare fibrin sealant patch (FSP; TachoSil; Takeda Pharma A/S) with oxidized regenerated cellulose gauze (ORCG; Surgicel Original; Ethicon) for the secondary treatment of local bleeding after hepatic resection in adult and pediatric patients. Primary end point was the proportion of adult patients with intraoperative hemostasis at the target bleeding site within 3 minutes of application of treatment.
Results |
Of 321 adult patients screened, 224 patients had minor to moderate bleeding from the hepatic resection area after primary hemostatic treatment and were intraoperatively randomized to FSP (n = 114) or ORCG (n = 110). Hemostasis within 3 minutes was achieved in 92 patients in the FSP group (80.7%) and 55 patients in the ORCG group (50.0%) (odds ratio = 4.87; 95% CI, 2.55–9.29; p < 0.001). The proportion of patients with hemostasis at 5 minutes was also higher in the FSP group (94.7% vs 76.4%; odds ratio = 6.24; 95% CI, 2.39–16.30; p < 0.001), and time to hemostasis was shorter (p < 0.001). At 10 minutes, hemostasis was achieved in all patients in the FSP group and 12 patients in the ORCG group (10.9%) had visible bleeding and required hemostatic rescue therapy. In pediatric patients, hemostasis at 3 minutes was achieved in 17 of 20 (85.0%) patients with FSP and 4 of 9 (44.4%) patients with ORCG. Both treatments were well tolerated in adults and children.
Conclusions |
The FSP (TachoSil) was safe and superior to ORCG (Surgicel Original) for achieving hemostasis in patients undergoing hepatic resection. ClinicalTrials.gov ID NCT01192022.
Le texte complet de cet article est disponible en PDF.Abbreviations and Acronyms : FSP, OR, ORCG, TEAE
Plan
| Disclosure Information: This study was sponsored by Takeda Pharma A/S. Dr Tetens is an employee of Takeda Pharma A/S. Dr Chapman received an honorarium from Novartis. |
Vol 222 - N° 3
P. 261-268 - mars 2016 Retour au numéro
Article précédent
- Training High-Volume Melanoma Surgeons to Perform a Novel Minimally Invasive Inguinal Lymphadenectomy: Report of a Prospective Multi-Institutional Trial
- James W. Jakub, Alicia M. Terando, Amod Sarnaik, Charlotte E. Ariyan, Mark B. Faries, Sabino Zani, Heather B. Neuman, Nabil Wasif, Jeffrey M. Farma, Bruce J. Averbook, Karl Y. Bilimoria, Jacob B. (Jake) Allred, Vera J. Suman, Travis E. Grotz, Benjamin Zendejas, Jeffrey D. Wayne, Douglas S. Tyler
- Roles of Sphincter of Oddi Laxity in Bile Duct Microenvironment in Patients with Cholangiolithiasis: From the Perspective of the Microbiome and Metabolome
- Tingbo Liang, Wei Su, Qi Zhang, Guogang Li, Shunliang Gao, Jianying Lou, Yun Zhang, Tao Ma, Xueli Bai
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?